Use: Once opened, use the product within 24 hours Suitable for athletes, with sweeteners
A second MDLMDL 3163was established in December 2025 specifically for NAION vision loss claims
Crucially, despite this variability, subsequent meta-analyses pooling the data from injectable GLP-1RAs have demonstrated a significant overall reduction in the risk of hospitalisation for HF with GLP-1RAs
Caution is needed with a history of pancreatitis, gallbladder disease, severe gastrointestinal conditions such as gastroparesis, diabetic retinopathy, or certain other medications, including insulin and sulfonylureas
The risks are amplified by the fact that most users buy untested, often contaminated, or mislabeled products from unregulated sources